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Introduction
Th  e emerging ﬁ  eld of regenerative medicine requires a 
reliable cell source in addition to biomaterial scaﬀ  olds 
and cytokine/growth factors. Th  e ‘cell’ is a particularly 
critical element for cell replacement therapies in order to 
provide a safe and suﬃ     cient cell supply for clinical 
applications. Eﬀ  orts to search for an adequate cell type 
and cell source have been conducted and have continued 
along with the discussions for their use in clinical 
application.
Th   ere are many potential cell sources for regenerative 
medicine, including bone marrow-derived mesenchymal 
stem cells, tissue-speciﬁ   c progenitor cells, embryonic 
stem (ES) cells, and induced pluripotent stem (iPS) cells. 
Although their biological potentials have been demon-
strated, none of these cells is widely accepted as a 
deﬁ  nitive cell source for clinical applications. Each cell 
type possesses diﬀ  erent advantages as well as limitations 
for their use, such as safety or availability. It will be 
helpful to search for a potential stem cell source from the 
perspective of its potential for clinical application. What 
is the sine qua non of the cells for clinically applicable 
regenerative medicine? At the end of this review, this 
question will be discussed further.
Th  ere is increasing evidence that the human placenta 
contains pluripotent or multipotent stem cells or both. 
Various multipotent stem cells have been isolated from 
diﬀ   erent parts of the human placenta, such as the 
amnion, chorion, umbilical cord, and fetal blood. As 
placenta-derived cells, these stem cells have common 
advantages (Figure 1). Speciﬁ  c types of placenta-derived 
stem cells, such as trophoblastic, hematopoietic, and 
mesen  chymal stroma cells, have been discussed else-
where [1-3]. Here, we will review stem cells derived from 
the amnion of human placentae, speciﬁ  cally  amniotic 
epithelial (AE) cells. First, we will summarize previous 
studies that have demonstrated the unique stem cell 
characteristics of AE cells. On the basis of these ﬁ  ndings, 
we introduce a model theory that explains why some AE 
cells, unlike other adult somatic stem cells, may possess 
pluripotent features. Second, we will discuss topics and 
pitfalls that are currently under discussion. Th  ird, 
previous works that are leading the therapeutic appli-
cation of AE cells will be summarized. Last, the potential 
of the clinical application of AE-derived stem cells and 
the future direction of the research are discussed.
Amniotic epithelial cells: what is so special about 
them?
Th  e epithelial cell population could be exclusively iso-
lated from the amnions of term human placentae by 
speciﬁ  c enzymatic digestion [4]. Th   e cell surface antigen 
proﬁ   le data indicate that AE cells are basically 
homogeneous cell populations for most of the cell surface 
markers [5]; however, the reactivity against ‘stem cell’-
speciﬁ  c antigens varies. Following isolation, some of the 
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speciﬁ  c embryonic antigen-3 (SSEA-3) and SSEA-4 and 
tumor rejection antigen 1-60 (TRA1-60) and TRA1-81, 
which are known to be expressed on human ES cells [6]. 
About 15%, 50%, and 5% to 10% of naïve human AE 
(hAE) cells are positive for SSEA-3, SSEA-4, and TRA 
stem cell markers, respectively [7]. Normally, undiﬀ  er  en-
tiated stem cells homogeneously express these stem cell 
markers [6]. Th   e variance of the ratio of stem cell marker-
positive cells indicates that naïve AE cell populations 
contain cells in various stage of ‘stemness’. Interestingly, 
the ratios of stem cell marker-positive AE cells (5% to 
50%) are considerably higher than for other somatic/
tissue stem cells. Most of the somatic/tissue stem cells 
are 0.1% to 0.01% of the residing tissue. For instance, the 
hematopoietic stem cell population is only 0.01% to 
0.05% of all bone marrow cells [8]. Th  e relatively high 
ratio of stem cell marker-positive cells in AE cell 
populations as somatic stem cells could be explained by 
the model theory. Th  e cell surface markers that are 
expressed by hAE cells are summarized and compared 
with the expression of other types of stem cells in Table 1 
[2,7,9-15].
Stem cells ‘left behind’: developmental uniqueness 
of the amniotic epithelial cell
Unlike other parts of the placenta, the amniotic epithe-
lium is a tissue of epiblastic origin. Human amnioblast is 
derived from the pluripotent epiblast around the eighth 
day following fertilization, whereas other parts of the 
placenta are derived from the trophectoderm. When the 
blastocyst is partially embedded in the endometrial 
stroma, the inner cell mass (or embryoblast) diﬀ  erentiates 
into two layers: the hypoblast and the epiblast. Th  e 
epiblast is the source of all three germ layers and 
eventually forms the developing embryo. At the same 
time, a small cavity (amniotic cavity) appears within the 
epiblast. Epiblast cells adjacent to the amniotic cavity 
(Figure 2) are called amnioblasts, which eventually form 
the amniotic epithelium. Concomitantly, some of the 
migrating hypoblasts transdiﬀ  erentiate  into  mesenchy-
mal cells (extraembryonic mesoderm) and develop into 
the amniotic connective tissue. Th  e epiblast-amnioblast 
segregation occurs before gastrulation, which is con-
sidered the ﬁ   rst dynamic event of organogenesis. All 
short-range organogenetic signals may not reach the 
segregated stem cells throughout gestation. For instance, 
cardiogenesis is a complex event that is orchestrated by 
short-range ﬁ  broblast growth factors (FGFs) and Hedge-
hog signals [16]. Th  erefore, some epiblasts/amnioblasts 
that are spatially segregated by the amniotic cavity from 
the epicenter of organogenesis may escape from these 
diﬀ  erentiation cues. After 10 months, although most of 
the cells have diﬀ  erentiated by following the epithelial 
cell fate and have lost their stem cell characteristics, 
about 5% to 10% of the AE cells may retain the epiblast-
like stem cell characteristics at term [7]. If this model 
theory is correct, fetal amniotic epithelium should con-
tain more stem cell marker-positive cells than term 
amniotic epithelium. Izumi and colleagues [17] demon-
strated that about 40% and 30% of fetal (early second 
trimester) AE cells are positive for stem cell markers 
TRA1-60 and TRA 1-81, respectively, whereas 5% of 
term AE cells are positive for these markers. Th  e  amnion 
is a fairly large tissue that may not be very uniform but is 
rather regionalized [18]. To exclude variances due to the 
Figure 1. Advantages of amniotic epithelial cells for clinical application. Fundamental advantages of placenta-derived stem cells and amniotic 
epithelial cell-specifi  c biological advantages are summarized. QOL, quality of life.
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harvested from three diﬀ  erent parts of the amnion: the 
center of the disc, the edge of the disc, and the membrane 
part. Th   ere was no signiﬁ  cant diﬀ  erence between samples 
by region, at least in these three parts [19]. On the other 
hand, the mechanism and signals that induce diﬀ  eren-
tiation on 90% of amnioblasts of epiblast origin are 
unclear. It has been shown that cultured AE cells secrete 
various morphogens and growth factors such as epider-
mal growth factor, Noggin, Activin [20], platelet-derived 
growth factor, vascular endothelial growth factor, angio-
genin, transforming growth factor-beta-2 (TGF-β2), and 
tissue inhibitors of metalloproteinases (TIMP-1 and 
TIMP-2) [21]. In addition to playing an important role in 
Table 1. Comparison of stem cell surface marker expression in stem cells
                            AE          ES  NS  MS  HS
First author  Fatimah  Bilic  Stadler  Banas  Parolini  Minas  Ilancheran  Miki  Osman     
Reference    [9] [10]  [11]  [12] [2] [13]  [14]  [5,7]  [15]     
c-met      +         + 
CCR4      −      ±  +    
CD10       +        + 
CD105     Up    +        + 
CD106  (VCAM-1)         −     + 
CD117  (c-kit)  −    −  ±    ±    +  +
CD13     Up    +        + 
CD14       −        
CD133      −      −  +  +  +  +
CD140b       +        
CD166  (ALCAM)    +     +        + 
CD24      +      +  +  +   
CD29       +  +      +  + 
CD31  (PECAM-1)  −         −     − 
CD324  (E-cadherin)       +  +    +  +    
CD338  (ABCG2)      +      +  +  +    +
CD34  −  −  −  −    −    −  +
CD349       −        
CD44  +  +  Up    +        + 
CD45  −  −     −        − 
CD49d       −        
CD49e    +  Up    +        
CD49f      +      +  +    
CD54  (ICAM-1)     +       +     + 
CD73  +  +     +        + 
CD9  +    +      +  +  +  
CD90  +   Up  Up  +  +      + 
GCTM2       +  +     +    
Sialyl  Lewis  a       +        
SSEA-1       −  −  −  −  −    
SSEA3   +  +  +  +  +  +    
SSEA4    + + + + + + + +     
TRA1-60      Down  + +    + + +     
TRA1-81      Down  + +    + + +     
−, negative; +, positive; ±, weak; AE, amniotic epithelial cell; Down, downregulated each antigen expression; ES, embryonic stem cell; HS, hematopoietic stem cell; MS, 
mesenchymal stem cell; NS, neural stem cell; SSEA, stage-specifi  c embryonic antigen; TRA, tumor rejection antigen; Up, upregulated each antigen expression.
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maturation or apoptosis to the epiblast-like immature AE 
cells. It must be noted that hAE cells are able to support 
the pluripotency of primate and mouse ES cells when 
primary hAE cells were used as feeder layer cells [22,23]. 
Th   ese data indicate that some of the secreted factors or 
cell-to-cell signaling (or both) might play a role in main-
taining epiblast-like stemness of some AE cells. Th  ere  are, 
however, no clear experimental data that indicate why 
the stem cell marker-positive AE cells unevenly diﬀ  er-
entiate even though all AE cells are exposed to the same 
environmental signals from the amniotic ﬂ  uid. One of the 
possible mechanisms is ‘lateral inhibition’, which is a type 
of cell-to-cell inter  action to regulate cell fate in the 
development of various cell types. Th  is could be an 
interesting question for further investigation.
Amniotic epithelial cells possess pluripotency?
In addition to expressing stem cell-speciﬁ  c surface markers, 
AE cells express molecular markers of pluri  potent stem 
cells: octamer-4 (OCT-4), NANOG,  sex deter  mining 
region Y-box 2 (SOX-2), Lefty-A, FGF-4, REX-1, and 
terato  carcinoma-derived growth factor 1 (TDGF-1) 
(cripto-1). Among those molecular stem cell markers, 
OCT-4 is known as one of the transcription factors that 
play a critical role in maintaining pluri  potency and self-
renewal. OCT-4 belongs to the POU family of trans  crip-
tional regulators [24-26] and regulates the pluripotency 
of human and mouse ES cells [27]. Expression of OCT-4 
is decreased along with the stem cell diﬀ  erentiation and 
the loss of expression leading to diﬀ  erentiation [28]. At 
the epiblast stage, OCT-4 con  tinues to be expressed as 
long as cells remain undiﬀ  er  entiated [26]. Th  e  expression 
of  OCT-4 is controlled epigenetically by hypermethy-
lation of the enhancer/promoter region [29].
OCT-4 protein expression is observed in most AE cells. 
Some display nuclear-localized OCT-4, but for the 
majority of AE cells, the expression is cytoplasmic. Th  ere 
is concern over the OCT-4 expression in somatic cells 
[30]. OCT-4 exists as two splice variants: OCT-4A and 
Figure 2. Illustration of ‘stem cell left behind’ theory. At 8 days after fertilization, inner cell mass diff  erentiates into epiblast and hypoblast. An 
amniotic cavity appears in the middle of the epiblast. As the cavity grows, the spatial segregation allows some amnioblasts to retain epiblast-like 
stem cells. Red stars indicate an amniotic cavity, and pink arrows indicate short-range organogenic signals that could not reach the amnioblasts.
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OCT-4A isoform that has the ability to confer and sustain 
pluripotency but that the OCT-4B may not be functional 
[32,33]. Lengner and colleagues [34] pointed out that 
published data describing positive results of OCT-4 
expression in somatic stem cells might be erroneous 
because of investigator ignorance of the two isoforms. 
Primers or antibodies that recognize both isoforms might 
be misused to claim functional OCT-4 expression in 
some somatic stem cells. We have conﬁ  rmed OCT-4A 
expression in naïve hAE cells by using a commercially 
available primer and probe set (Hs0300511_g1; Applied 
Biosystems, Foster City, CA, USA) that matches OCT-
4A-speciﬁ  c exons [17].
Although a number of investigations have provided 
evidence that suggests multipotency of AE cells, the 
pluripotency has not yet been proven. One of the critical 
issues is the diﬃ   culty to establish clonal expansion from a 
single AE cell, a step that is essential to demonstrate 
pluri potency  in vitro. Unlike mouse ES cells, human ES 
cells and mouse epiblast-derived stem (EpiSC) cells are 
intolerant to passaging as single cells. Like EpiSC cells, 
AE cells do not maintain their stem cell characteristics 
well or survive as a single cell in culture. AE cells easily 
fall into the senescence state or diﬀ  er  entiate into palm-
shaped epithelial cells when cultured at low density. Th  e 
teratoma formation assay has been used as a gold 
standard assay to prove pluripotency of ES or iPS cells. 
However, this assay cannot be applied to evaluate AE 
cells. Because of the genetically stable charac  ter  istics, the 
AE cell does not form a teratoma when injected into 
immunodeﬃ   cient mice [7,14]. Th   e ultimate approach to 
determine pluripotency of AE-derived stem cells is 
generating chimeric animals. If an AE cell that is injected 
into the blastocyst will contribute to all germ layer cells 
in the resulting chimeric embryo, the pluri  potency will 
be conﬁ  rmed. In 2004, Tamagawa and colleagues [35] 
derived cell lines from human amnion and mixed them 
with mouse early embryonic stem cells to form an 
aggregation chimera. Th  e authors succeeded in demon-
strating that the human cells contributed to all three 
primordial germ layer formations in the xenogeneic 
chimera embryo [35]. Although the cell line cells are 
established from a mixed amniotic cell population that 
contains both AE cells and amniotic mesenchymal ﬁ  bro-
blasts, this investigation suggested the pluripotency of 
the human amniotic cells. Further investigation will be 
required to clarify which cell population is responsible 
for the pluripotency.
Multipotency of amniotic epithelial cells and the 
therapeutic potential
Although the pluripotency of a single AE cell is not 
clariﬁ  ed yet, AE cells diﬀ  erentiate into cells of all three 
germ layers under appropriate culture conditions [7,14]. 
Th   e changes of gene expression and cell morphology of 
AE cells in these experiments demonstrated the AE cell 
plasticity that is induced by exposure to exogenous 
growth factors or chemicals. At present, it has not been 
conﬁ  rmed whether a single pluripotent amniotic stem 
cell diﬀ  erentiates into all three germ layers or whether 
there are various lineage-committed multipotent cells in 
the AE cell population. In spite of this critical question 
from a basic science point of view, it is a secondary con-
cern from the perspective of clinical application. Since it 
is impossible to simultaneously induce the desired 
diﬀ  erentiation in 100% of the starting material of stem 
cells, some form of puriﬁ  cation process is essential prior 
to using stem cell-derived therapeutic cells in clinical 
application. Th   erefore, the most impor  tant question from 
a clinical point of view is whether therapeutically useful 
cells can be produced from the hAE cell population. 
Here, we summarize previous works that suggest the 
diﬀ  erentiation potential of AE cells and the therapeutic 
potential tested in animal models.
It must be noted that there are developmental and 
anatomical diﬀ   erences between rodent and human 
amnion. Rodent amniotic epithelium is clearly derived 
from epiblasts; therefore, the usage of rodent AE cells as 
a model could be appropriate. However, owing to the size 
and anatomical uniqueness, the isolation of AE cells must 
be done very carefully. Recently, Dobreva and colleagues 
[36] focused on the species diﬀ  erences of the amnion and 
comprehensively reviewed this topic. Th  is review is 
strongly recommended to researchers who plan to con-
duct research with rodent amnion stem cells, including 
amniotic ﬂ  uid-derived stem cells.
Ectoderm lineage
Neurodegenerative diseases are among the most suitable 
target diseases for stem cell-based therapies. Since 
neuro  degenerative diseases have many pathological 
processes in common, the cell transplantation approach 
could potentially ameliorate the symptoms of several 
distinct neurodegenerative diseases. Th   ere are two 
expected mechanisms of cell transplantation. One is the 
diﬀ   erentiation potential of the transplanted stem/
progenitor cells to neural cells. Sakuragawa’s group [37], 
pioneers in AE research, demonstrated that cultured AE 
cells express markers of glial and neuronal progenitor 
cells. Our group conﬁ  rmed that naïve hAE cells express 
various neural marker genes, including neuron-speciﬁ  c 
enolase, neuro  ﬁ   lament-M, myelin basic protein, 
microtubule-associated protein 2, and glial ﬁ  brillary acid 
protein [7]. Under appropriate culture conditions, AE 
cells express or up  regu  late neuron-speciﬁ  c gene expres-
sions such as nestin and glutamic acid descarboxylase. 
Using the adenoviral labeling system, Ishii and colleagues 
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oligodendrocyte marker genes, myelin basic protein, 
proteolipid protein, and 2’,3’-cyclic nucleotide 3’-phos-
pho diesterase  (CNPase). Th   e neural diﬀ  erentiation capa-
bilities of AE cells were conﬁ  rmed by various researchers 
[39,40]. Amazingly, the capabilities were preserved even 
after long-term cryopreservation. Human amniocytes 
that were originally isolated in 1974 adopted neuronal 
morphology and expression of neural genes, including β-
III-tublin, Gap-43, NF-M, TAU, and synaptophysin, after 
more than 30 years [41].
Th   e other expectation of cell transplantation for neuro-
degenerative diseases is the ability to secrete functional 
or protective factors from the transplanted cells such as 
dopamine or some other factors, which result in 
protective/trophic eﬀ  ects or immunomodulatory eﬀ  ects 
[42,43]. For instance, in Parkinson’s disease, there is a loss 
of the dopaminergic neural population in the substantia 
nigra [44]. In clinical settings, it has been shown that 
dopamine-producing tissue (fetal mesen  cephalic grafts) 
transplantation could ameliorate the symptoms [45]. hAE 
cells synthesize and release dopamine [46,47]. Th  e 
dopamine synthesis responds to supplemented L-DOPA 
(L-3,4-dihydroxy  phenyl  alanine) concentration in a dose-
dependent manner. Furthermore, transplanted AE cells 
might release neuroprotective factors or induce neuro-
genesis to improve diseased or damaged environments or 
both. It has been shown that hAE cells produce and 
secrete various types of trophic factors such as nerve 
growth factor, neurotrophin-3, and brain-derived neuro-
trophic factor [48-51].
Th  is neural diﬀ  erentiation and neurotrophic potential 
of hAE cells has been tested in animal models. Trans-
planted hAE cells alleviated Parkinson-like symptoms in 
a dopamine-denervated rat model [52]. In these experi-
ments, the engrafted hAE cells showed paracrine or 
neurotrophic eﬀ  ects rather than a contribution via neural 
diﬀ  erentiation. However, when rat AE cells were trans-
planted into ischemic hippocampus of adult gerbils, the 
rat AE-derived neuron-like cells were observed after 
5 weeks of the transplantation [53]. Th   e neural diﬀ  eren-
tiation and the therapeutic eﬀ  ect of AE cells were also 
tested in a rat stroke model. Th   e transplanted hAE cells 
migrated to the ischemic area and reduced infarct volume 
and improved behavioral function [54]. Recently, Suh 
[55] reported that hAE cell transplantation restored 
memory function in a transgenic mouse model of 
Alzheimer’s disease. Although the mechanism is under 
investigation, these data encourage the clinical applica-
tions of the hAE cells for neurodegenerative diseases.
Endoderm lineage
Two cell types, hepatocytes and insulin-producing pan-
creatic cells, are most desired among the endoderm 
lineage cells. Both cells have been used for cell replace-
ment therapies and their therapeutic concept and eﬃ   ci-
ency have been shown [56-59]. Th  e  insuﬃ   cient supply of 
human hepatocytes or beta cells, however, is one of the 
reasons that prevent these promising therapies from 
becoming standard clinical applications. Th  us, safe and 
constant supplies of these functional cells are urgently 
required. In addition, stem cell-derived hepatocytes will 
be useful not only for cell replacement therapy (hepato-
cyte transplantation) [57] but also for toxicology and 
drug development [60].
Sakuragawa and colleagues [61] reported that cultured 
hAE cells expressed and produced albumin and α-feto-
protein in vitro and in vivo. Th   e hepatic character  istics of 
hAE cells were extensively investigated by Takashima and 
colleagues [62]. Our group applied a step-wise exogenous 
growth factor stimulation protocol to induce further 
hepatic maturation in hAE cells [63]. Th  e AE-derived 
hepatocyte-like cells expressed late-phase hepatic diﬀ  er-
en  tiation markers, including various inducible cyto-
hrome P450 genes, which are essential for drug meta-
bolism as functional hepatocytes. Th  ese cells were also 
transplanted into immunodeﬁ  cient mice, and human α-1 
antitrypsin was detected circulating in the serum of 
recipient mice, and this conﬁ   rmed that the engrafted 
hAE cells function as hepatocytes in mouse liver. 
Recently, Manuelpillai and colleagues [64] transplanted 
hAE cells into drug-induced cirrhosis model animals and 
demonstrated the anti-ﬁ  brosis eﬀ  ect of hAE cells.  Th  e 
data indicate that the therapeutic eﬀ  ect of transplanted 
hAE cells is more likely the immunomodulatory eﬀ  ect by 
suppressing inﬂ  ammatory activation of hepatic stellate 
cells. On the other hand, the authors demonstrated human 
albumin in mouse sera that might be secreted from 
diﬀ  erentiated hAE-derived hepatic cells. Rat amniotic cells 
have been isolated and used to simulate allogeneic cell 
transplantation [65-67]. Th  e transplanted rat AE cells 
survived in the liver following allogeneic transplantation 
for at least 30 days [65]. Although the rodent amniotic cell 
property might be diﬀ   erent from that of humans, the 
therapeutic eﬃ   ciency of AE cells, together with the basal 
advantages of the placenta-derived stem cells, suggests a 
treatment option for liver diseases.
Several groups demonstrated the pancreatic diﬀ  eren-
tia  tion potential of hAE cells [7,68,69]. Under appropriate 
culture conditions, pancreatic cell-related genes such as 
PDX-1, PAX-6, NKX2.2, insulin, and glucagon were up-
regulated in vitro [7]. Th   e therapeutic potential was also 
demonstrated by the transplantation of cultured hAE 
cells in the spleen of diabetic mice. Th  e serum glucose 
levels were normalized for several months after the trans-
plant, suggesting that the transplanted AE cells diﬀ  er-
entiated into insulin-producing beta cells [68]. Th  is 
ﬁ  nding was later conﬁ  rmed with comprehensive analyses 
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tion [69]. In vitro diﬀ   erentiation and involvement of 
histamine nicotinamide-induced pancreatic diﬀ  erentia-
tion were further investigated [70].
In addition to the hepatic and pancreatic diﬀ  eren-
tiation, the capability of AE cells diﬀ  erentiating into other 
types of endoderm lineage cells has been reported. 
Moodley and colleagues [71] demonstrated that naïve 
human amnion epithelial cells diﬀ   erentiate into lung 
epithelium (type II pneumocyte) 2 weeks after parenteral 
injection into a bleomycin-induced lung injury SCID 
(severe combined immunodeﬁ  ciency) mice model. Th  e 
transplanted hAE cells reduced inﬂ  ammation and abro-
gated ﬁ  brosis post-lung injury. Moritoki and colleagues 
[72] systemically transplanted EGFP (enhanced green 
ﬂ   uorescent protein)-transgenic mice AE cells into 
chemically induced cholestasis mouse model animals. 
Th  e EGFP and cholangiocyte marker CK7 double-
positive cells formed a bile duct-like tubular structure in 
the chronic cholestatic mouse liver.
Mesoderm lineage
Because adult cardiomyocytes do not regenerate suﬃ   -
ciently, there is great interest in ﬁ   nding suitable cell 
sources for cellular cardiomyoplasty. hAE cells also 
possess the potential to diﬀ  erentiate into cardiac cells [7]. 
Although AE-derived cardiomyocyte-like cells expressed 
cardiac diﬀ   erentiation marker genes, immunocyto-
chemistry analysis showed that the expression pattern of 
α-actinin was similar to that of immature cardiomyocytes. 
Th   e therapeutic potential was demonstrated by using rat 
amniotic cells and a rat acute infarction model [73]. 
Although transplanted rat amniotic cells dramatically 
improved the cardiac function, only a few transplanted 
cells were diﬀ  erentiated into cardiomyocytes (α-actinin-
positive cells). Th  e therapeutic eﬀ  ect was speculated to 
be due to paracrine or immuno  modu  latory eﬀ  ects of the 
rat amniotic cells. An interesting application of amniotic 
membrane was tested, and the therapeutic eﬃ   ciency was 
demonstrated. Cargnoni and colleagues [74] applied a 
fragment of human amniotic membrane as a cardiac 
patch on an infarction area of a rat heart. Th  e post-
ischemic cardiac function was signi  ﬁ    cantly  improved 
with the amnion patch. Th  is investi  gation importantly 
demonstrated that secondary cardiac ischemic injury 
could be prevented by humoral factors that are released 
from the amnion. Recently, functional cardiac 
diﬀ   erentiation of human amniotic cells was demon-
strated [75]. Th  e cardiomyogenic diﬀ  erentiation was in-
duced by a co-culture system with murine fetal cardio-
myocytes. Th   e structure of sarcomeric α-actinin and the 
spontaneous beating and in vivo contribution of human 
amnion-derived cardiomyocytes were demon  strated. 
Stem cell-derived cardiomyocytes are also expected to be 
an important new tool for drug development [60]. Th  e  in 
vitro functional hAE-derived cardiomyocytes could be a 
cell source for these assays. Further investigation for 
culture condition optimization or direct reprogramming 
will be required along with a deﬁ  nition  of  selection 
markers of functional mature cardiomyocytes. Th  e 
studies that demonstrate the diﬀ  erentiation capability of 
AE cells into all three germ layer lineages are summarized 
in Table 2.
Advantages of human amniotic epithelial cells for 
clinical applications
From the view of clinicians and patients, the sine qua non 
of clinically applicable stem cells is ﬁ  rst, ‘safety’; second, 
‘therapeutic eﬃ     ciency’; and, last, ‘availability/suﬃ   cient 
quantity’. Several types of stem cells could serve as cell 
sources for cellular therapy. Generally, stem cells are 
classiﬁ   ed according to their diﬀ   erentiation ability and 
origin. Pluripotent stem cells, such as ES cells and iPS 
cells, are considered to be the most promising stem cells 
because of their tremendous diﬀ  erentiation ability. Th  e 
‘safety’, however, is always a concern. Th  e pluripotency 
comes with genetical instability, which leads to concerns 
for tumorigenicity. Although the ‘therapeutic eﬃ   ciency’ 
is promised, the long-term eﬃ   ciency has not yet been 
proven. Furthermore, the expansion and maintenance to 
obtain a therapeutically suﬃ   cient number of cells require 
time, eﬀ  ort, and cost.
Adult stem cells can be derived from virtually any 
tissue or organ. Most adult stem cells are tissue-speciﬁ  c 
lineage-committed multipotent cells. Some adult stem 
cells such as mesenchymal stem cells and hematopoietic 
stem cells are already applied in clinics and showed 
therapeutic eﬃ   ciency, mainly with their immuno  modu-
latory property. Th  erefore, the clinical applications are 
considerably safe, particularly in the case of autologous 
transplantation.
A similar immunomodulatory property has been 
demonstrated with hAE cells [76-80]. hAE cells inhibited 
allogeneic mixed lymphocyte reactions in a dose-
dependent manner with 66% to 93% inhibition [81]. Most 
of the report demonstrated the immunomodulatory 
eﬀ  ect by secretion of suppressive mediators such as TNF-
α, FasL, TRAIL, TGF-β, and MIF. On the other hand, 
Banas and colleagues [12] demon  strated that the 
immunomodulatory eﬀ  ect of AE cells is dependent on 
cell-to-cell contact with responding T  cells. By using 
non-serum culture conditions, the authors demonstrated 
that hAE cells inhibit peripheral blood mononuclear cell 
proliferative responses to mito  gen, alloantigen, and recall 
antigen but preactivated T-cell blast response. Th  e  results 
suggested that the presence of HLA-G immunological 
cell surface molecules is responsible for the cell-to-cell 
immunosuppressive properties of AE cells. In addition to 
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comple  ment inhibitory proteins, CD59 antigen, decay-
accelerating factor, mem  brane attack complex, and Fas 
antigen/CD95/APO1 have been reported as potential 
immunoregulatory factors from hAE cells [85-88]. 
Never  theless, further investigation is required to fully 
elucidate the underlying mechanisms of the immuno-
modu latory  eﬀ  ect of hAE cells.
Importantly, the safety of AE upon transplantation has 
been shown in a clinical setting. hAE cells have been used 
in clinics to correct lysosomal storage disease [89-91]. 
Although the applications were not conducted as a stem 
cell therapy, more than 50 cases of AE cell/tissue trans-
plantations have been performed in various institutes 
[90-92]. No tumor formation has been reported from 
these clinical trials. As it has been described, AE cells are 
clearly non-tumorigenic when transplanted into immuno-
deﬁ  cient animals [7,14]. A total of one to two million 
hAE cells was injected into more than 50 individual mice, 
which were observed for a maximum of 516 days. None 
of the AE cell transplants has led to the development of 
tumors by any route of administration in SCID-beige 
mice or Rag-2 knockout mice. In parallel, cytogenetic 
analysis conﬁ  rmed genetical stability of cultured AE cells 
[7]. AE cells do not express telomerase reverse trans  crip-
tase (TERT) mRNA [7]. A study demonstrated that 
immortalized cells by expression of TERT could exhibit 
some neoplastic transformation toward what seem to be 
cancer stem cells [93]. Missing TERT expression may be 
a safety advantage. Since more than 100 million cells can 
be isolated from one placenta, long-term culture and 
massive replication are not required to use AE cells as a 
cell source. For instance, only half a million cells will be 
suﬃ     cient to improve the devastating symptoms of 
Parkinson’s disease and Huntington’s disease [94,95]. 
Furthermore, human placenta is a neonatal tissue that 
has less age-acquired and environmental DNA damage. 
Naturally, the neonatal cells should possess a life-long 
Table 2. Diff  erentiation potential of amniotic epithelial cells
Lineage  Cell type  Species  First author  Reference
Ectoderm  Neural progenitor cell  Human  Sakuragawa  [37]
 Dopamine-producing  cell  Human  Kakishita  [47,52]
 Neural  cell  Human  Miki  [7]
 Oligodendrocyte    Human  Ishii  [38]
 Neural  cell  Human  Niknejad  [40]
 Neural  cell  Human  Woodbury  [41]
 Neuronal  Rat  Okawa  [53]
 Neural  Rat  Marcus [67]
Mesoderm Adipogenic  Human  Ilancheran  [14]
 Chondrogenic  Human  Ilancheran  [14]
 Osteogenic  Human  Stadler  [11]
 Cardiomyogenic  Human  Miki  [7]
 Cardiomyogenic  Human  Tsuji  [75]
 Cardiomyogenic  Rat  Fujimoto  [73]
Endoderm Hepatic  Human  Miki  [7,63]
 Hepatic  Human  Sakuragawa  [61]
 Hepatic  Human  Takashima  [62]
 Hepatic  Human  Manuelpillai  [64]
 Hepatic  Rat  Nakajima  [65]
 Hepatic  Rat  Takahashi  [66]
 Hepatic  Rat  Marcus [67]
 Insulin-producing  cell  Human  Miki  [7]
 Insulin-producing  cell  Human  Wei  [68]
 Insulin-producing  cell  Human  Hou  [69]
 Insulin-producing  cell  Human  Szukiewicz  [70]
 Bile  duct  Mouse  Moritoki  [72]
 Pneumocyte  Human  Moodley  [71]
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for clinical application.
A placenta is discarded after every live birth; objections 
to derive stem cells from placentae are not expected. 
Isolating and using stem cells from discarded human 
tissue are ultimate recycling biotechnologies, which 
would be acceptable in today’s society. Human placenta is 
readily available tissue wherever human society exists. 
Th  erefore, there will be no regional disparities for 
placenta-derived stem cell therapies. Current statistics 
indicate that there are over 4 million births and over 1 
million cesarean sections performed in the US every year. 
Th   e sheer volume of available placenta tissue leads us to 
the idea of establishing a biobank system for placenta-
derived stem cells. Nakatsuji and colleagues [96] 
estimated that a cell bank with only 30 stem cell lines 
could match the HLA-A, HLA-B, and HLA-DR 
haplotypes in 82.2% of the Japanese population. On the 
basis of these estimations and the theoretical number of 
available placentae, it is clearly feasible to establish a 
biobank that stores human placenta-derived stem cells 
with all HLA haplotypes. Clinically relevant stem cells 
should be easily and reproducibly cultured and 
manipulated. Th   e AE cell isolation procedure is relatively 
easy and does not require a special laboratory set-up [4]. 
Th   e biobanking system therefore could be established in 
any country and connected as a network to provide all 
HLA types, including race dominant types.
Ethical issues surrounding both embryonic and fetal 
stem cells do not apply to the use of discarded human 
placentae. However, once the therapeutic eﬃ   ciency  of 
placenta-derived stem cells is demonstrated, this 
normally discarded medical waste may turn into valuable 
property. Th  e cell-acquiring process, cost, and propri-
etary rights will be new ethical issues. A regulatory-
compliant system will be required for cell-acquiring and 
-providing pro  cesses. Th   e precedent and current 
regulations for the umbilical cord blood cell usage could 
be useful to prepare a guideline for procure  ments of 
placenta-derived stem cells [97].
Th  e use of this ideal stem cell could take one of two 
directions in future clinical regenerative medicine. One 
direction will be in developing technology to derive 
pluripotent stem cell lines from AE cells, which possess a 
biological potential equivalent to that of ES cells and iPS 
cells. Th   is direction, however, may eliminate the AE cell 
advantage that is discussed here. Th   e other direction is to 
aim directly at diﬀ  erentiation to obtain functional target 
cells. Th  e stem cell-derived cell therapy requires a 
selection step prior to the cell application to patients to 
ensure safety and eﬃ   ciency.  Th  e genetic stability and 
non-tumorigenicity of AE cells will be the advantage for 
this approach. Unlike in ES cells or iPS cells, leakage 
concerns at the selection step will not be a critical issue.
Conclusions
Herein, we reviewed the stem cell characteristics of 
amnion cells, especially AE cells. We introduced a model 
theory that may explain why so many cells with stem cell 
features are present in the amnion. Th   e model theory has 
been proposed by several research teams, including ours 
[5,7,14,34]. Previous studies that demonstrate the diﬀ  er-
en  tiation and therapeutic potential of AE cells were sum-
marized. We described four major reasons why placenta-
derived cells are a signiﬁ   cant cell source for clinical 
applications. Th   e AE cell meets two important conditions 
that are required for clinically relevant stem cells: safety 
and availability.  So far, no stem cells are able to 
diﬀ  erentiate into therapeutically useful cell types in vitro, 
or their diﬀ  erentiation is not well controlled. As with 
other types of stem cells, further investigations will be 
required to induce AE cells to diﬀ  erentiate into thera-
peutically useful cells. Since AE cells are extremely safe 
and show thera  peutic eﬃ   ciency in animal models, clinical 
applica  tion should be considered in the near future.
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